Biogen’s stock hit by soft guidance and a decline in sales of MS drugs
1 month ago
10
ARTICLE AD BOX
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset below-consensus EPS outlook.